Reduced prophylactic effect of tixagevimab-cilgavimab in patients with hematological malignancies and without antibody response after SARS-COV-2 vaccination

Eur J Haematol. 2023 Oct;111(4):668-670. doi: 10.1111/ejh.14045. Epub 2023 Jul 18.

Authors

Chiara Callegari¹, Davide Lazzarotto¹, Alessandra Soravia¹, Martina Mutti², Pietro Lauzzana¹, Maddalena Peghin³, Stefano Cordella², Renato Fanin¹, Anna Candoni^{1

2}

Affiliations

¹ Division of Hematology and Stem Cell Transplantation Unit, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy.
² Division of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy.
³ Division of Infectious Diseases, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy.

PMID: 37461815
DOI: 10.1111/ejh.14045

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal
Antibody Formation
COVID-19 Vaccines / adverse effects
COVID-19* / prevention & control
Hematologic Neoplasms* / complications
Hematologic Neoplasms* / therapy
Humans
SARS-CoV-2
Vaccination

Substances

COVID-19 Vaccines
tixagevimab
Antibodies, Monoclonal
cilgavimab